Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score.
Senni M, Parrella P, De Maria R, Cottini C, Böhm M, Ponikowski P, Filippatos G, Tribouilloy C, Di Lenarda A, Oliva F, Pulignano G, Cicoira M, Nodari S, Porcu M, Cioffi G, Gabrielli D, Parodi O, Ferrazzi P, Gavazzi A. Senni M, et al. Int J Cardiol. 2013 Feb 20;163(2):206-11. doi: 10.1016/j.ijcard.2011.10.071. Epub 2011 Nov 29. Int J Cardiol. 2013. PMID: 22130225
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. Solomon SD, et al. Lancet. 2012 Oct 20;380(9851):1387-95. doi: 10.1016/S0140-6736(12)61227-6. Epub 2012 Aug 26. Lancet. 2012. PMID: 22932717 Clinical Trial.
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. McMurray JJ, et al. Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5. Eur J Heart Fail. 2013. PMID: 23563576 Free PMC article. Clinical Trial.
Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome.
Cioffi G, Mortara A, Di Lenarda A, Oliva F, Lucci D, Senni M, Cacciatore G, Chinaglia A, Tarantini L, Metra M, Maggioni AP, Tavazzi L; Italian Acute Heart Failure Survey. Cioffi G, et al. Among authors: senni m. Int J Cardiol. 2013 Oct 9;168(4):3691-7. doi: 10.1016/j.ijcard.2013.06.020. Epub 2013 Jul 11. Int J Cardiol. 2013. PMID: 23850320
Natriuretic peptides and the Framingham risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study.
Iacovoni A, De Maria R, Gavazzi A, Grosu A, Fontana A, Guideri S, Gori M, Ferrari P, Filippi A, Rutili MR, Donzelli L, Parolini M, Senni M. Iacovoni A, et al. Among authors: senni m. Int J Cardiol. 2013 Oct 12;168(5):5093-5. doi: 10.1016/j.ijcard.2013.07.260. Epub 2013 Aug 3. Int J Cardiol. 2013. PMID: 23962783 No abstract available.
In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, Metra M, Lucci D, Gonzini L, Cirrincione V, Montagna L, Di Lenarda A, Maggioni AP, Tavazzi L; IN HF Outcome Investigators. Senni M, et al. Int J Cardiol. 2014 May 1;173(2):163-9. doi: 10.1016/j.ijcard.2014.02.018. Epub 2014 Feb 22. Int J Cardiol. 2014. PMID: 24630337
Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).
Vaduganathan M, Dei Cas A, Mentz RJ, Greene SJ, Khan S, Subacius HP, Chioncel O, Maggioni AP, Konstam MA, Senni M, Fonarow GC, Butler J, Gheorghiade M; EVEREST Trial Investigators. Vaduganathan M, et al. Among authors: senni m. Am J Cardiol. 2014 Sep 1;114(5):743-50. doi: 10.1016/j.amjcard.2014.05.064. Epub 2014 Jun 24. Am J Cardiol. 2014. PMID: 25060414 Free PMC article. Clinical Trial.
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. McMurray JJ, et al. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. N Engl J Med. 2014. PMID: 25176015 Free article. Clinical Trial.
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, Kraigher-Krainer E, Shah AM, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Jhund PS, et al. Circ Heart Fail. 2014 Nov;7(6):953-9. doi: 10.1161/CIRCHEARTFAILURE.114.001427. Epub 2014 Oct 2. Circ Heart Fail. 2014. PMID: 25277997 Clinical Trial.
468 results